[{"id":"2b8a33cf-62f0-4cf9-ab2c-6563d734fd34","acronym":"","url":"https://clinicaltrials.gov/study/NCT05760612","created_at":"2023-03-08T17:01:51.251Z","updated_at":"2025-02-25T13:55:01.559Z","phase":"Phase 3","brief_title":"A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment with Trastuzumab Combined with Parezumab","source_id_and_acronym":"NCT05760612","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 amplification • HER-2 amplification + HR-positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 amplification • HER-2 amplification + HR-positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Nerlynx (neratinib) • Perjeta (pertuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 02/16/2028","primary_completion_date":" 02/16/2028","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2024-11-28"},{"id":"c1de4320-1800-4ab1-8b43-eb87d669c526","acronym":"","url":"https://clinicaltrials.gov/study/NCT01730833","created_at":"2021-01-18T07:33:38.779Z","updated_at":"2025-02-25T12:25:57.142Z","phase":"Phase 2","brief_title":"Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer","source_id_and_acronym":"NCT01730833","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • HER-2 amplification + HR-positive • HER-2 overexpression + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • HER-2 amplification + HR-positive • HER-2 overexpression + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 07/17/2013","start_date":" 07/17/2013","primary_txt":" Primary completion: 01/12/2021","primary_completion_date":" 01/12/2021","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-15"}]